Shareholders Equity: The sum of preferred and common equity items.
Calidi Biotherapeutics, Inc. (CLDI) had Shareholders Equity of $4.93M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-4.42M |
|
-- |
|
-- |
|
$4.19M |
|
$-4.19M |
|
$0.08M |
|
$-4.10M |
|
$-4.10M |
|
$-4.11M |
|
$-4.11M |
|
$-4.11M |
|
$-4.11M |
|
$-4.19M |
|
$-3.76M |
|
10.31M |
|
10.31M |
|
$-0.43 |
|
$-0.43 |
|
| Balance Sheet Financials | |
$7.35M |
|
$0.76M |
|
$2.24M |
|
$9.59M |
|
$3.84M |
|
$0.75M |
|
$0.82M |
|
$4.66M |
|
$4.93M |
|
$4.93M |
|
|
Shareholders Equity |
$4.93M |
11.79M |
|
| Cash Flow Statement Financials | |
$-4.12M |
|
$-0.01M |
|
$5.16M |
|
$5.82M |
|
$6.85M |
|
$1.03M |
|
$0.23M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.92 |
|
-- |
|
-- |
|
0.13 |
|
0.18 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-4.12M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-83.24% |
|
-83.24% |
|
-42.83% |
|
-72.30% |
|
$0.42 |
|
$-0.40 |
|
$-0.40 |
|